Tibet Weixinkang Medicine Co., Ltd. (SHA:603676)
China · Delayed Price · Currency is CNY 11.25
-0.18 (-1.57%)
Feb 4, 2026, 2:45 PM CST
Tibet Weixinkang Medicine Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,168 | 1,300 | 1,322 | 1,398 | 1,033 | 715.57 |
Other Revenue | 0.22 | 0.22 | 0.34 | 0.23 | 0.3 | 0.1 |
| 1,168 | 1,300 | 1,323 | 1,399 | 1,034 | 715.67 | |
Revenue Growth (YoY) | -6.97% | -1.70% | -5.43% | 35.30% | 44.43% | -3.41% |
Cost of Revenue | 482.83 | 604.25 | 651.24 | 672.06 | 502.71 | 385.12 |
Gross Profit | 685.46 | 695.98 | 671.41 | 726.48 | 530.92 | 330.55 |
Selling, General & Admin | 339.05 | 347.42 | 403.84 | 483.97 | 389.59 | 264.36 |
Research & Development | 115.83 | 116.01 | 112.82 | 72.45 | 38.02 | 21.3 |
Other Operating Expenses | -14.39 | 10.89 | 11.8 | 15.29 | 11.94 | 8.68 |
Operating Expenses | 438.84 | 473.99 | 526.33 | 571.95 | 437.99 | 293.12 |
Operating Income | 246.62 | 221.99 | 145.07 | 154.54 | 92.92 | 37.43 |
Interest Expense | -0.2 | -0.22 | -0.34 | -0.19 | -0.11 | - |
Interest & Investment Income | 18.14 | 20.54 | 17.74 | 19.08 | 13.3 | 14.59 |
Currency Exchange Gain (Loss) | -0.1 | -0.1 | -0.13 | - | - | 0 |
Other Non Operating Income (Expenses) | -36.7 | -0.25 | -0.31 | -0.08 | -4.77 | -0.84 |
EBT Excluding Unusual Items | 227.76 | 241.95 | 162.02 | 173.34 | 101.34 | 51.19 |
Gain (Loss) on Sale of Investments | 25.14 | 2.97 | 11.58 | - | - | - |
Gain (Loss) on Sale of Assets | -1.98 | -2.02 | -0.57 | 0.13 | 0.06 | -0.02 |
Asset Writedown | -19.01 | -15.61 | - | -14.13 | -3.25 | -0.17 |
Other Unusual Items | 42.73 | 49.3 | 42.8 | 23.02 | 16.08 | 18.62 |
Pretax Income | 274.64 | 276.6 | 215.84 | 182.36 | 114.23 | 69.62 |
Income Tax Expense | 52.56 | 30.43 | 1.82 | 5.4 | 18.32 | 11.2 |
Earnings From Continuing Operations | 222.08 | 246.17 | 214.02 | 176.96 | 95.91 | 58.42 |
Net Income | 222.08 | 246.17 | 214.02 | 176.96 | 95.91 | 58.42 |
Net Income to Common | 222.08 | 246.17 | 214.02 | 176.96 | 95.91 | 58.42 |
Net Income Growth | -10.11% | 15.02% | 20.94% | 84.50% | 64.16% | 4.93% |
Shares Outstanding (Basic) | 428 | 432 | 428 | 432 | 417 | 417 |
Shares Outstanding (Diluted) | 428 | 432 | 428 | 432 | 417 | 417 |
Shares Change (YoY) | -0.84% | 0.90% | -0.83% | 3.50% | -0.08% | -2.56% |
EPS (Basic) | 0.52 | 0.57 | 0.50 | 0.41 | 0.23 | 0.14 |
EPS (Diluted) | 0.52 | 0.57 | 0.50 | 0.41 | 0.23 | 0.14 |
EPS Growth | -9.34% | 14.00% | 21.95% | 78.26% | 64.29% | 7.69% |
Free Cash Flow | 122.94 | 314.61 | 170.3 | 168.46 | 115.09 | 79.35 |
Free Cash Flow Per Share | 0.29 | 0.73 | 0.40 | 0.39 | 0.28 | 0.19 |
Dividend Per Share | 0.327 | 0.342 | 0.285 | 0.235 | 0.160 | 0.095 |
Dividend Growth | -26.85% | 20.00% | 21.28% | 46.88% | 68.42% | 111.11% |
Gross Margin | 58.67% | 53.53% | 50.76% | 51.95% | 51.37% | 46.19% |
Operating Margin | 21.11% | 17.07% | 10.97% | 11.05% | 8.99% | 5.23% |
Profit Margin | 19.01% | 18.93% | 16.18% | 12.65% | 9.28% | 8.16% |
Free Cash Flow Margin | 10.52% | 24.20% | 12.88% | 12.04% | 11.13% | 11.09% |
EBITDA | 295.8 | 268.43 | 187.85 | 190.8 | 124.53 | 68.52 |
EBITDA Margin | 25.32% | 20.64% | 14.20% | 13.64% | 12.05% | 9.57% |
D&A For EBITDA | 49.18 | 46.44 | 42.78 | 36.27 | 31.6 | 31.08 |
EBIT | 246.62 | 221.99 | 145.07 | 154.54 | 92.92 | 37.43 |
EBIT Margin | 21.11% | 17.07% | 10.97% | 11.05% | 8.99% | 5.23% |
Effective Tax Rate | 19.14% | 11.00% | 0.84% | 2.96% | 16.04% | 16.08% |
Revenue as Reported | 1,168 | 1,300 | 1,323 | 1,399 | 1,034 | 715.67 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.